Collectively, these mechanisms emphasize that the cardioprotective benefits of SGLT2 inhibitors are largely independent of glycemic control, highlighting their role as disease-modifying therapies in T2DM patients at high cardiovascular risk [19,20]. Here, SLC5A2 is linked to type 2 diabetes mellitus.